Evidence map›Paper›PMID 18312841›Full record

ArticleCell host & microbe2008

Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus.

Kirsten Schneider, Andrea Loewendorf, Carl De Trez, James Fulton, Antje Rhode, Heather Shumway, Sukwon Ha, Ginelle Patterson, Klaus Pfeffer, Sergei A Nedospasov and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell host & microbe, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 141 citations in OpenAlex.

  1. Trial
  2. B cells help cross-priming antiviral CD8⁺ T cells.Cellular & molecular immunology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Immune surveillance of cytomegalovirus in tissues.Cellular & molecular immunology · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Kirsten SchneiderDivision of Molecular Immunology, La Jolla Institute for Allergy and Immunology 9420 Athena Circle, La Jolla, CA 92037, USA.
Andrea Loewendorf
Carl De Trez
James Fulton
Antje Rhode
Heather Shumway
Sukwon Ha
Ginelle Patterson
Klaus Pfeffer
Sergei A Nedospasov
Carl F Ware
Chris A Benedict
La Jolla Institute for Immunology · USEngelhardt Institute of Molecular Biology · RUHeinrich Heine University Düsseldorf · DE

Funding

SPHINGOMYELIN SIGNALING PATHWAY IN FAS-INDUCED APOPTOSISP01CA069381 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 1996 to 2009
$16.8M
Anti-herpesvirus Signaling by LTalphabeta/LIGHT CytokinesR01AI048073 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2001 to 2016
$7.0M
HVEM-BTLA system in InflammationR01AI067890 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2007 to 2016
$4.3M
Lymphotoxin alpha Beta and LIGHT cytokine systemsR37AI033068 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2003 to 2012
$4.2M
Modulating Lymphotoxins for Viral DefensesR01AI057840 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI WARE, CARL F · 2005 to 2009
$2.4M
SURFACE LYMPHOTOXIN A/B COMPLEXESR01AI033068 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI WARE, CARL F · 1994 to 2002
$1.0M
Activation of innate antiviral defenses by LTbetaRR21AI061549 · NIAID · LA JOLLA INST FOR ALLERGY &IMMUNOLGY · PI BENEDICT, CHRISTOPHER A · 2004 to 2005
$560k
NCI NIH HHS CA69381NCI NIH HHS P01 CA069381NIAID NIH HHS AI057840NIAID NIH HHS AI061549NIAID NIH HHS AI33068NIAID NIH HHS AI48073NIAID NIH HHS R01 AI033068NIAID NIH HHS R01 AI048073NIAID NIH HHS R01 AI057840NIAID NIH HHS R01 AI067890NIAID NIH HHS R21 AI061549NIAID NIH HHS R37 AI033068
6 · The paper itself

Abstract

Toll-like receptor (TLR)-dependent pathways control the production of IFNalphabeta, a key cytokine in innate immune control of viruses including mouse cytomegalovirus (MCMV). The lymphotoxin (LT) alphabeta-LTbeta receptor signaling pathway is also critical for defense against MCMV and thought to aid in the IFNbeta response. We find that upon MCMV infection, mice deficient for lymphotoxin (LT)alphabeta signaling cannot mount the initial part of a biphasic IFNalphabeta response, but show normal levels of IFNalphabeta during the sustained phase of infection. Significantly, the LTalphabeta-dependent, IFNalphabeta response is independent of TLR signaling. B, but not T, cells expressing LTbeta are essential for promoting the initial IFNalphabeta response. LTbetaR expression is required strictly in splenic stromal cells for initial IFNalphabeta production to MCMV and is dependent upon the NF-kappaB-inducing kinase (NIK). These results reveal a TLR-independent innate host defense strategy directed by B cells in communication with stromal cells via the LTalphabeta cytokine system.

Indexed as

AnimalsB-LymphocytesHerpesviridae InfectionsImmunity, InnateInterferon Type ILymphotoxin alpha1, beta2 HeterotrimerLymphotoxin beta ReceptorMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMuromegalovirusNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesReceptor Cross-TalkReceptors, Tumor Necrosis FactorInterferon Type ILymphotoxin alpha1, beta2 HeterotrimerLymphotoxin beta ReceptorNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesReceptors, Tumor Necrosis Factor

Identifiers

PMID18312841
PMCPMC2703178
OpenAlexW2135793489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.